-
Mashup Score: 9Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis☆ - 2 year(s) ago
In hormone receptor-positive (HoR+) breast cancer (BC), gene expression analysis identifies luminal A (LumA), luminal B (LumB), human epidermal growth factor receptor 2 (HER2)-enriched (HER2-E), basal-like (BL) intrinsic subtypes and a normal-like group. This classification has an established prognostic value in early-stage HoR+ BC. Here, we carried out a trial-level meta-analysis to determine…
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy - 2 year(s) ago
Annually, >1.2 million new cases of prostate cancer are diagnosed and global prostate cancer-related deaths exceed 350 000 per annum, making it one of the leading causes of cancer-associated death in men.1 Despite major improvements in the systemic treatment of advanced prostate cancer, metastatic prostate cancer remains an incurable disease with an overall survival (OS) of only 30% at 5 years…
Source: Esmo OpenCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
https://t.co/ys8Phl0E0U see new article for discussion!
-
-
Mashup Score: 0Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy - 2 year(s) ago
Annually, >1.2 million new cases of prostate cancer are diagnosed and global prostate cancer-related deaths exceed 350 000 per annum, making it one of the leading causes of cancer-associated death in men.1 Despite major improvements in the systemic treatment of advanced prostate cancer, metastatic prostate cancer remains an incurable disease with an overall survival (OS) of only 30% at 5 years…
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet-
Please vote on your views re. the next PRO and CON discussion just published in @ESMO_Open: Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy https://t.co/yKA25wY9Y4
-
-
Mashup Score: 0Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma - 2 year(s) ago
More than 80% of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) patients harbor the (nucleophosmin) NPM1-ALK fusion gene t(2;5) chromosomal translocation. We evaluated the preclinical and clinical efficacy of ceritinib treatment of this aggressive lymphoma.
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet-
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma @ESMO_Open @myESMO https://t.co/OR0vtF8PVs
-
-
Mashup Score: 2Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy - 2 year(s) ago
BRAF activation occurs as part of the mitogen-activated protein kinase (MAPK) cellular signaling pathway which leads to increased cellular proliferation and survival. Mutations in BRAF can result in unbridled activation of downstream kinases with subsequent uncontrolled cellular growth that formulate the basis for oncogenesis in multiple tumor types. Targeting BRAF by selective inhibitors has…
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet-
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy - ESMO Open https://t.co/OV3yNXYPrQ
-
-
Mashup Score: 1
Malignant ascites is common in metastatic pancreatic cancer (mPC) and its management still remains a clinical challenge. Early identification of patients at risk for ascites development may support and guide treatment decisions.
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet-
Another clinically important publication in @ESMO_Open: Clinical risk factors for ascites in metastatic pancreatic cancer. https://t.co/dCP3PtfCfT
-
-
Mashup Score: 5
The use of immune checkpoint inhibitors (ICIs) in the front-line treatment of advanced non-small-cell lung cancer (NSCLC) is currently the standard of care. However, as clinical trials include a very limited number of elderly patients, evidence on the safety and efficacy of using ICI-based regimens is still limited.
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet-
Another clinically highly relevant topic just published in @ESMO_Open by @myESMO: #Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell #lungcancer: results of an International Experts Panel Meeting. https://t.co/VFwu8oBg29
-
-
Mashup Score: 1223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy - 2 year(s) ago
Bone-seeking radiopharmaceuticals can deposit radiation selectively to some osteosarcoma tumours because of the bone-forming nature of this cancer.
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet-
223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy @ESMO_Open @myESMO https://t.co/zTOyBBimL4
-
-
Mashup Score: 3Anti-TIGIT therapies for solid tumors: a systematic review - 2 year(s) ago
Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new therapies are under investigation, such as anti-TIGIT [anti-T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif…
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VriesElisabeth: Anti-TIGIT therapies for solid tumors: a systematic review https://t.co/hdoAtfArfR
-
-
Mashup Score: 4Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy - 2 year(s) ago
BRAF activation occurs as part of the mitogen-activated protein kinase (MAPK) cellular signaling pathway which leads to increased cellular proliferation and survival. Mutations in BRAF can result in unbridled activation of downstream kinases with subsequent uncontrolled cellular growth that formulate the basis for oncogenesis in multiple tumor types. Targeting BRAF by selective inhibitors has…
Source: Esmo OpenCategories: Hem/Oncs, Latest HeadlinesTweet-
⚡️Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy @myESMO @ESMO_Open @OncoAlert 🧬🎯 #precisionmedicine https://t.co/AGFS54BvDS https://t.co/Te7ldwRPl3
-
RT @prat_aleix: Our new article is out @ESMO_Open 🎉 Amazinly led by @FrancescoSche20 https://t.co/RGAzbPVetU Prognostic value of intrin…